Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytochrome P450-Mediated Metabolism of Antimycobacterial <i>N</i>α-Aroyl-<i>N</i>-aryl-phenylalanine Amides.

ACS infectious diseases·2026
Same author

`3-Hydroxy-6H,7H-chromeno [3,4-c]chromene-6,7-dione as a Substrate for Studying Glucuronidation, Sulfonation and Lactone Hydrolysis.

Drug metabolism and bioanalysis letters·2026
Same author

Designing fluorescent estrogen mimetic 7-hydroxycoumarin probe substrates for human sulfotransferase enzymes.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Novel inhibitors of bromodomain and extra-terminal domain trigger cell death in breast cancer cell lines.

Bioorganic & medicinal chemistry·2024
Same author

TRPA1 Inhibition Effects by 3-Phenylcoumarin Derivatives.

ACS medicinal chemistry letters·2024
Same author

SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors.

Pharmaceuticals (Basel, Switzerland)·2023
Same journal

CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics.

Drug metabolism and drug interactions·2014
Same journal

In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism.

Drug metabolism and drug interactions·2014
Same journal

Effect of silymarin pretreatment on the bioavailability of domperidone in healthy human volunteers.

Drug metabolism and drug interactions·2014
Same journal

Systems Medicine in the era of 'Big Data': a game-changer for Personalized Medicine?

Drug metabolism and drug interactions·2014
Same journal

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.

Drug metabolism and drug interactions·2014
Same journal

Effect of selective cyclooxygenase-2 inhibitor lumiracoxib on phenolsulfonphthalein disposition in rats.

Drug metabolism and drug interactions·2014
See all related articles

Related Experiment Video

Updated: May 21, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

CYP2A6: genetics, structure, regulation, and function.

Hannu Raunio1, Minna Rahnasto-Rilla

  • 1Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, Kuopio, Finland. hannu.raunio@uef.fi

Drug Metabolism and Drug Interactions
|June 19, 2012
PubMed
Summary
This summary is machine-generated.

The CYP2A6 gene, crucial for metabolizing nicotine, exhibits significant genetic variation. Certain CYP2A6 gene variants lead to reduced or absent enzyme activity, impacting smoking behavior and lung cancer risk.

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Overexpression and Purification of Human Cis-prenyltransferase in Escherichia coli
07:35

Overexpression and Purification of Human Cis-prenyltransferase in Escherichia coli

Published on: August 3, 2017

Related Experiment Videos

Last Updated: May 21, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Overexpression and Purification of Human Cis-prenyltransferase in Escherichia coli
07:35

Overexpression and Purification of Human Cis-prenyltransferase in Escherichia coli

Published on: August 3, 2017

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Biochemistry

Background:

  • The human CYP2A gene subfamily includes CYP2A6, CYP2A7, and CYP2A13.
  • CYP2A6 is highly polymorphic, with numerous allelic variants.
  • Some variants result in complete loss of CYP2A6 enzyme activity.

Purpose of the Study:

  • To investigate the role and significance of the CYP2A6 gene.
  • To highlight CYP2A6's substrate specificity and genetic variability.
  • To explore the implications of CYP2A6 activity on nicotine metabolism and associated health risks.

Main Methods:

  • Analysis of CYP2A6 gene polymorphisms and allelic variants.
  • Assessment of CYP2A6 protein expression in human tissues, primarily liver and nasal mucosa.
  • Evaluation of CYP2A6 substrate metabolism using coumarin as a marker and nicotine elimination studies.

Main Results:

  • CYP2A6 exhibits limited substrate specificity, primarily metabolizing coumarin and nicotine.
  • Approximately 80% of nicotine is eliminated via CYP2A6.
  • A strong correlation exists between CYP2A6 genotypes, smoking habits, and lung cancer susceptibility.

Conclusions:

  • CYP2A6 genetic variability significantly influences nicotine metabolism.
  • CYP2A6 genotype is a key factor in understanding individual differences in smoking behavior.
  • CYP2A6 plays a critical role in lung cancer risk assessment for smokers.